Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptional profiling of skin tumor samples from mice with combintions of Braf, Alk5, p53, Tgfbr2 and Kras mutations

ABSTRACT: Transcriptional profiling of skin tumor samples from mice with combintions of Braf, Alk5, p53, Tgfbr2 and Kras mutations

PROVIDER: PRJNA818280 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18397819_1.fastq.gz	Fastqsanger.gz
	SRR18397819_2.fastq.gz	Fastqsanger.gz
	SRR18397820_1.fastq.gz	Fastqsanger.gz
	SRR18397820_2.fastq.gz	Fastqsanger.gz
	SRR18397821_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 80

Similar Datasets

Transcriptional profiling of skin tumor samples from mice with combintions of Braf, Alk5, p53, Tgfbr2 and Kras mutations

Project description:Murine skin tumors following combintions of Braf, Alk5, p53, Tgfbr2 and Kras mutation, under the control of Lgr5CreER.

2023-03-18 | GSE199070 | GEO

microRNA expression profile between KRAS/BRAF wild and BRAF mutant colorectal cancer

Project description:The genome-wide miRNA expression analysis was performed in clinical samples, comprising 15 BRAF-mutant and 15 non-KRAS/BRAF-mutant colorectal cancers by using a SurePrint G3 Human miRNA microarray. clinical samples, comprising 15 BRAF-mutant and 15 non-KRAS/BRAF-mutant colorectal cancers by using a SurePrint G3 Human miRNA microarray.

2016-04-01 | E-GEOD-66548 | biostudies-arrayexpress

microRNA expression profile between KRAS/BRAF wild and BRAF mutant colorectal cancer

2016-04-01 | GSE66548 | GEO

Quantitative Analysis of p53 and/or TGFBR2 Knockdown Endothelial Transcriptomes after Irradiation

Project description:Transcriptional profiling p53 or TGFBR2 knockdown HUVECs with or without irradiation.

2018-10-26 | GSE118538 | GEO

GNPS - Oncogenic KRAS and BRAF drive metabolic reprogramming in colorectal cancer JEH 2016

Project description:Multiplexed PRM analysis for metabolic reprogramming in isogenic cell lines with KRAS or BRAF mutations.

2016-02-01 | MSV000079486 | GNPS

Comparative transcriptome analysis of Ptf1aCre;Kras,Brg1-/- vs. Ptf1a;Kras;p53+/- subcutaneous pancreatic ductal adenocarcinoma

Project description:In this experiment the RNA of s.c. grown tumors of cancer cell lines of murine Ptf1aCre;Kras,Brg1-/- vs. Ptf1a;Kras;p53+/- PDA was isolated and analyzed for gene expression. Ptf1aCre;Kras,Brg1-/- s.c. PDA grows more benign as compared to Ptf1a;Kras;p53+/- PDA; and the rationale of this study was to identify genes responsible for this different biological behavior. Total RNA of s.c. tumors of Ptf1aCre;Kras,Brg1-/- vs. Ptf1a;Kras;p53+/- cancer cell lines was isolated, purified and analyzed on the deep sequencing platform.

2013-11-14 | E-GEOD-52332 | biostudies-arrayexpress

Oncogenic KRAS(G12V) and BRAF(V600E) in intestinal organoids

Project description:Goals of the study was to compare transcripional and phenotypic response of mouse intestinal organoid cultures to the KRAS(G12V) or BRAF(V600E)oncogenes.

2018-06-02 | GSE115234 | GEO

Oncogenic KRAS and BRAF drive metabolic reprogramming in colorectal cancer JEH 2016

Project description:Multiplexed PRM analysis for metabolic reprogramming in isogenic cell lines with KRAS or BRAF mutations.

2016-02-01 | MSV000079486 | MassIVE

Integrated functional genomics and craniofacial morphogenesis within the FaceBase Consortium: Alk5 and TGFBR2 mutants

Project description:Integrated functional genomics and craniofacial morphogenesis within the FaceBase Consortium: Alk5 and TGFBR2 mutants

| PRJNA360626 | ENA

Mutant KRAS/BRAF Reprograms the Enhancer Landscape via GATA1 to Drive Chemoresistance

Project description:Despite advances in the detection and management of colorectal cancers, resistance to anti-cancer therapies remains a significant challenge. Activating mutations in KRAS and BRAF are frequently observed in colorectal cancers and have been associated with aggressive tumors and poor survival after chemotherapy. In the present study, we demonstrate that mutations in KRAS/BRAF alter the enhancer landscape of tumor cells, which leads to the resistance of the cornerstone colorectal cancer chemotherapeutic agent 5-fluorouracil (5-FU) through activation of transcription factor GATA1. Targeted inhibition of GATA1 reverses epigenetic changes in KRAS mutant cells and restores sensitivity to 5-FU. These results indicate a novel therapeutic opportunity for tailoring individualized therapy in human colorectal cancer.

2019-10-01 | GSE115400 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data